

CITATION REPORT

List of articles citing

In the *Zzz* zone: the effects of Z-drugs on human performance and driving

DOI: 10.1007/s13181-013-0294-y

Journal of Medical Toxicology, 2013, 9, 163-71.

Source: <https://exaly.com/paper-pdf/55870943/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
136	Orexin receptor antagonists as therapeutic agents for insomnia. 2013 , 4, 163		32
135	Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope. 2014 , 9, e112068		24
134	The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. 2014 , 8, 3		27
133	Use of benzodiazepines and related drugs in Manitoba: a population-based study. 2014 , 2, E208-16		40
132	Sleep loss, sleep disorders and driving accidents. 2014 , 12, 96-105		9
131	Sedative Hypnotics. 2014 , 499-532		1
130	A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. 2014 , 10, 1093-100		20
129	Advances in the Management of Primary and Secondary Insomnia. 2014 ,		
128	The sirens of sleep?. 2014 , 89, 579-82		1
127	Insomnia in the setting of cancer. 2014 , 32-54		
126	Premeditated double infanticide by zopiclone administration. 2015 , 27, 251-254		1
125	Amnestic Somnambulism and Nocturnal Eating Disorder Associated with Zolpidem Use as a Contributing Factor in Accidental Death. 2015 , 5, 352-358		
124	Common sleep disorders increase risk of motor vehicle crashes and adverse health outcomes in firefighters. 2015 , 11, 233-40		74
123	Quality measures for the care of patients with insomnia. 2015 , 11, 311-34		32
122	Insomnia, hypnotic use, and health-related quality of life in a nationally representative sample. 2015 , 24, 1223-33		22
121	Benzodiazepine Abuse and Addiction. 2015 , 343-365		2
120	Psychopharmacological strategies in the management of posttraumatic stress disorder (PTSD): what have we learned?. 2015 , 17, 564		49

119	Trazodone and cognitive performance in Alzheimer disease. 2015 , 35, 88-9	8
118	Psychotropic medication use in hospitalized patients with borderline personality disorder. 2016 , 6, 68-74	4
117	Understanding and reducing the prescription of hypnotics and sedatives at the interface of hospital care and general practice: a protocol for a mixed-methods study. 2016 , 6, e011908	7
116	Characterization of patients with duplicated z-hypnotic use: A population-based study in Taiwan. 2016 , 7, 60-63	
115	Zolpidem use and risk of fractures: a systematic review and meta-analysis. 2016 , 27, 2935-44	20
114	Sustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population. 2016 , 67, 1012-8	21
113	Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. 2016 , 96, 255-270	57
112	Benzodiazépines et personnes âgées. 2016 , 16, 246-257	0
111	Driving impairment. 2016 , 153-178	
110	Assessment of cognitive safety in clinical drug development. 2016 , 21, 445-53	7
109	Investigation of the usefulness of zaleplon at two doses to induce afternoon-sleep under noise interference and its effects on psychomotor performance and vestibular function. 2016 , 3, 5	1
108	Implementing Computer-Based Psychotherapy Among Veterans in Outpatient Treatment for Substance Use Disorders. 2016 , 67, 176-83	10
107	Safety and Tolerability of Anxiolytics/Sedative-Hypnotics. 2016 , 191-207	1
106	Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. 2016 , 59, 504-30	71
105	The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. 2016 , 41, 1144-55	12
104	Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. 2017 , 267, 149-161	4
103	Geriatric Polypharmacy: Pharmacist as Key Facilitator in Assessing for Falls Risk. 2017 , 33, 205-223	3
102	The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. 2017 , 142, 204-214	3

101	Delivering CBT for Insomnia in Psychosis. 2017 ,	4
100	Synthesis of functionalized imidazo[1,2-a]pyridines via domino A3-coupling/cycloisomerization approach. 2017 , 53, 409-412	7
99	Relationship between the use of benzodiazepines and falls in older adults: A systematic review. 2017 , 101, 17-22	48
98	Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research. 2017 , 17, 493-507	115
97	Symptom Presentation and Prescription of Sleep Medications for Veterans With Posttraumatic Stress Disorder. 2017 , 205, 112-118	9
96	LC-MS-MS with Post-Column Reagent Addition for the Determination of Zolpidem and its Metabolite Zolpidem Phenyl-4-carboxylic Acid in Oral Fluid after a Single Dose. 2017 , 41, 735-743	4
95	Z-drug for schizophrenia: A systematic review and meta-analysis. 2017 , 256, 365-370	8
94	Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. 2018 , 70, 197-245	131
93	The Effect of Lowering the Legal Drink-Drive Limit on the Toxicological Findings in Driver Fatalities: A Comparison of Two Jurisdictions. 2018 , 63, 1457-1465	5
92	Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. 2018 , 47, 201-208	47
91	Oral Sedation. 2018 , 95-119	0
90	Mesoporous particle-based microcontainers for intranasal delivery of imidazopyridine drugs. 2018 , 35, 657-666	7
89	Use of Sedative-Hypnotics and Mortality: A Population-Based Retrospective Cohort Study. 2018 , 14, 1669-1677	13
88	Structural characterization and Hirshfeld surface analysis of a Co complex with imidazo[1,2-]pyridine. 2018 , 74, 600-606	30
87	Prescription Drugs Used in Insomnia. 2018 , 13, 169-182	17
86	Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea. 2018 , 32, 593-600	4
85	Ten-year trend in sleeping pills use in Switzerland: the CoLaus study. 2019 , 64, 56-61	5
84	Reducing unnecessary sedative-hypnotic use among hospitalised older adults. 2019 , 28, 1039-1045	2

83	The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. 2020 , 43,	6
82	The acute effects of aerobic exercise on sleep in patients with depression: study protocol for a randomized controlled trial. 2019 , 20, 352	3
81	Sleep Promoting Effects of IQP-AO-101: A Double-Blind, Randomized, Placebo-Controlled Exploratory Trial. 2019 , 2019, 9178218	1
80	The effects of aerobic, resistance, and meditative movement exercise on sleep in individuals with depression: protocol for a systematic review and network meta-analysis. 2019 , 8, 105	4
79	Mild Cognitive Impairment and Dementia. 2019 , 253-276	
78	Geriatric Polypharmacy: Pharmacist as Key Facilitator in Assessing for Falls Risk: 2019 Update. 2019 , 35, 185-204	1
77	Sleep Disorders. 2019 , 341-376	
76	Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients. 2019 , 26, 1243-1253	7
75	Preoperative Sedative-hypnotic Medication Use and Adverse Postoperative Outcomes. 2021 , 274, e108-e114	7
74	The interplay of context factors in hypnotic and sedative prescription in primary and secondary care-a qualitative study. 2019 , 75, 87-97	7
73	Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use. 2020 , 17, 156-164	15
72	Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?. 2020 , 136, 109501	2
71	Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. 2020 , 60, 1642-1654	12
70	Advancements in chemical methodologies for the synthesis of 3-arylimidazo[1,2-a]pyridines: an update of the decade. 2020 , 50, 3507-3534	4
69	The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. 2020 , 15, 2286-2305	10
68	Sedatives and hypnotics. 2020 , 42, 67-79	1
67	Prescription Drugs Used in Insomnia. 2020 , 15, 133-145	11
66	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. 2019 , 11, 344	14

65	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. 2021 , 136, 543-551	2
64	Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. 2021 , 133, 71-81	12
63	Effects of Psychopharmacological Medicines upon Driving Ability. 2021 , 1-15	
62	Sedatives and Hypnotics Abuse. 2021 ,	
61	Non-apnea sleep disorder and its risk for all kinds of injuries: A 14-year follow-up for a nationwide population-based retrospective study. <i>Medicine (United States)</i> , 2021 , 100, e24766	1.8 0
60	Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study. 2021 , 2,	1
59	An Undifferentiated Spell: The Answer is in The Pillbox. 2021 , 96, 2003-2005	0
58	Missbrauch und Abhängigkeit von Benzodiazepinen und Z-Drugs. 2021 , 40, 636-647	
57	Sleep and the Fitness to Drive: A Swiss Perspective.	0
56	Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. 2021 , 238, 2693-2708	7
55	Longitudinal effects of using and discontinuing CNS medications on cognitive functioning.	
54	BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights. 2021 ,	1
53	Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999-2015. 2020 , 3, e2028557	14
52	Eszopiclone for insomnia. 2018 , 10, CD010703	11
51	Advanced Sleep-Wake Rhythm Disorder. 2020 , 109-122	2
50	Substance Use Disorders: A Biopsychosocial Perspective. 2020 ,	2
49	Is the regulation of Z-drugs in Brazil in line with scientific research and international standards?. 2018 , 40, 112	1
48	[Acute insomnia: natural course and correction modalities]. 2019 , 119, 28-35	4

47	Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study. 2019 , 21, e13371		6
46	Efficacy and safety of low-dose doxepin in depressed patients suffering from insomnia: a retrospective, naturalistic case series analysis. 2014 , 16,		2
45	New-Onset Visual Hallucinations With Eszopiclone. 2016 , 18,		1
44	Lorediplon: A New GABAA Modulator Drug for Treatment of Insomnia. 2015 , 121-145		0
43	Development of New Therapeutical Agents for Treatment of Insomnia and Other Sleeps Disorders. 2015 , 85-107		
42	Arzneimitteltherapiesicherheit und besondere Verfahren. 2018 , 971-1009		
41	Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study (Preprint).		
40	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 380-435		
39	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , xxiii-xxiv		
38	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 67-92		
37	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 539-592		
36	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 213-254		
35	Effect of magnetic stimulation of Shenmen point on cognitive function of chronic insomnia: A randomized controlled clinical trial. <i>Medicine (United States)</i> , 2020 , 99, e23807	1.8	2
34	Traffic Medicine. 2020 , 495-538		1
33	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 3-31		
32	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 32-66		
31	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 95-119		
30	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 120-162		

29	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 165-212		
28	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 255-302		
27	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 305-338		
26	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 339-379		
25	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 436-483		
24	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 484-538		
23	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 593-620		
22	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 623-678		
21	Substance Use Disorders: A Biopsychosocial Perspective. 2020 , 679-791		
20	Driving performance assessments for benzodiazepine receptor agonist-related impairment: a scoping review protocol. <i>JBI Evidence Synthesis</i> , 2021 , 19, 242-250	2.1	2
19	Benzodiazepine and Nonbenzodiazepine Hypnotics (Z-Drugs): The Other Epidemic. 2021 , 141-156		0
18	Use of potentially driver-impairing drugs among older drivers.. <i>BMC Geriatrics</i> , 2022 , 22, 4	4.1	0
17	Arzneimitteltherapiesicherheit und besondere Verfahren. 2022 , 1071-1113		
16	Short- and Long-Term Influences of Benzodiazepine and Z-Drug Use in Patients with Bipolar Disorder Combined Sleep Disturbance during Affective Period: A Nine-Month Follow-Up Analysis. <i>Disease Markers</i> , 2022 , 2022, 1-7	3.2	
15	Circuits and components of delta wave regulation. <i>Brain Research Bulletin</i> , 2022 ,	3.9	0
14	Mindfulness-based Cognitive Therapy to Improve Sleep Quality in Older Adults with Insomnia. <i>Psychosocial Intervention</i> , 2022 , 000-000	3.1	
13	An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019. <i>Drugs and Aging</i> ,	4.7	
12	An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update. 2022 , 317, 114840		1

11	Prescription Drugs Used in Insomnia. 2022 , 17, 315-328	0
10	Case Report: High doses of Zolpidem and QT interval lengthening: Is there a relationship? A case series. 13,	0
9	Fast and simple preparation of a sensor based on electrochemically reduced graphene oxide (rGO) for the determination of zopiclone in pharmaceutical dosage by square wave adsorptive stripping voltammetry (SWAdSV).	0
8	Effects of Psychopharmacological Medicines upon Driving Ability. 2022 , 4339-4353	0
7	Longitudinal effects of using and discontinuing CNS medications on cognitive functioning.	0
6	Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy Endpoints from the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.	0
5	Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics.	1
4	To sleep or not to sleep â€”Effects on memory in normal aging and disease. 2023 , 3, 100068	0
3	The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. 2023 , 240, 699-711	0
2	Discovery of Small-Molecule Antagonists of Orexin 1/2 Receptors from Traditional Chinese Medicinal Plants with a Hypnotic Effect. 2023 , 16, 542	0
1	The orexin story and orexin receptor antagonists for the treatment of insomnia.	0